Tildrakizumab and Quality of Life: Deep Dive into the Impact of Psoriasis and Treatment on Different Domains-Should Psychosocial Life Impairment Be Considered a Comorbidity? in Journal of clinical medicine / J Clin Med. 2025 Jan 2;14(1):223. doi: 10.3390/jcm14010223.

2025
ASL Torino 4
AOU Città della Salute di Torino

Tipo pubblicazione

Journal Article

Autori/Collaboratori (21)Vedi tutti...

Faure E
Dermatology Unit, Policlinico di Milano Ospedale Maggiore Fondazione IRCCS Ca', 18001 Granada, Italy.
Papaianni V
Dermatology Unit, A.O.U. P. "G. Martino", 98121 Messina, Italy.
Giordano D
Dermatology Unit, A.O.U. Sant'Andrea, 00042 Roma, Italy.

et alii...

Abstract

Background/Objectives: Psoriasis is a chronic inflammatory skin disease that may have a significant impact on patients' quality of life. Alongside clinical scores, treatment goals include improvements in patients' quality of life, divided into its social, working and psychosocial life aspects. Indeed, psychological impairment should always be considered in the management of moderate-to-severe psoriasis. Tildrakizumab, an anti-IL-23, is approved for the management of moderate-to-severe psoriasis. Both clinical trials and real-life studies show its efficacy and safety; however, no studies have evaluated how tildrakizumab may improve different domains of quality of life, including physical, psychological, and social aspects of patients' quality of life. The objective was to evaluate the effectiveness of tildrakizumab in the management of moderate-to-severe psoriasis, focusing on the impact on all domains of patients' quality of life. Methods: A 28-week multicenter, real-life, retrospective study was performed enrolling patients affected by moderate-to-severe psoriasis undergoing treatment with tildrakizumab. PASI and DLQI were evaluated at each follow-up (W16, W28). A sub-analysis of each DLQI question evaluated different domains of quality of life, including physical, psychological, and social aspects of patients' quality-of-life. Results: A total of 62 patients were enrolled. At week 28, 97.1%, 85.7%, and 54.3% of patients achieved PASI75, PASI90, and PASI100, respectively. DLQI showed a significant reduction from baseline (20.3 ± 5.5) to week 28 (0.9 ± 2.2, p < 0.0001), with up to 82.9% achieving DLQI < 1. Sub-analysis of each question (Q1-Q10) showed a reduction in the value of each answer from baseline to week 28. Conclusions: The results confirm tildrakizumab as an effective and safe treatment in real life, positively affecting all domains of quality of life, with significant impact already appreciable at week 16 of follow-up.

Accesso banca dati bibliografica

PMID : 39797306

DOI : 10.3390/jcm14010223

Keywords

tildrakizumab; quality of life; psoriasis;